Nathan Singh

Returning to Twitter (brielfy) to share publication of our article "BACH2 regulates T cell lineage state to enhance CAR T cell function" today in Nature Immunology! rdcu.be/eZlwj 1 of 3 studies (!) (others led by @RoychoudhuriLab and Tuoqi Wu) published together that...

The paper is part of three parallel submissions from @NathanSinghLab & Tuoqi Wu arriving at similar conclusions - that the dosage of BACH2 and the timing of its induction are key to enhancing #celltherapy for cancer. @Cambridge_Uni @CRUKCambridge

Thanks also to Ben Youngblood for the hilarious News and Views that accompanies.

identify the central role of BACH2 in T cell lineage decisions and function. A real pleasure working with the NI team and these great investigators! A great example complementary instead of competitive work strengthening the observation!

Returning to Twitter (brielfy) to share publication of our article "BACH2 regulates T cell lineage state to enhance CAR T cell function" today in Nature Immunology! rdcu.be/eZlwj 1 of 3 studies (!) (others led by @RoychoudhuriLab and Tuoqi Wu) published together that...

Cell Therapy Keystone 2025 is coming! If you're interested in cell engineering, immunotherapy, cancer or autoimmunity (!) this meeting is for you! Join us in Banff for a fantastic symposium this March. Abstract deadline 12/9! @lab_rezvani keystonesymposia.org/conferences/co…

@HindRafei @YuSungHsu1 @lab_rezvani @ImmunologyGSBS Is there a way to triple like a picture? ❤️

Immensely proud to celebrate Kevin @YuSungHsu1 as our newly coated PhD student! It has been a pleasure to mentor you together with @lab_rezvani! Your passion and talent will undoubtedly make a significant impact in the field! Here’s to your bright future ahead! @ImmunologyGSBS

@EvanWeberPhD this is WILD!

An absolutely bonkers stat from this Nature article on Nobel Prize winners. "702 out of 736 researchers who have won science and economics prizes up to 2023 are part of the same academic family" nature.com/immersive/d415…

@HindRafei @YuSungHsu1 @ImmunologyGSBS @lab_rezvani @MDAndersonNews Woohoo! Go Kevin!

Incredibly proud of our superstar PhD student @YuSungHsu1 for delivering an outstanding talk at the Cancer Biology retreat this afternoon @ImmunologyGSBS! Very excited about all the great work he is doing to improve our CAR NK cells in solid tumors @lab_rezvani @MDAndersonNews

There is no cavalry coming. No miracle solution. No saviors. In the end, we, the American people-not any of our institutions-have to save our democracy by registering and voting in defense of our freedoms the next two months. We are the cavalry. The responsibility is ours.

Checkout our paired Perspective and Priority Brief in @CIR_AACR! Amazing collab with @carlhjune, @JoeFraietta and @GillSaar that we hope will help researchers, product developers and regulators advance gene edited T cell therapies. aacrjournals.org/cancerimmunolr…

Incredibly creative work highlighting the broad applications of T cell immunotherapy - congrats Jony and team!

Looking for a small meeting with leaders in cell therapy discussing high impact translational research? Look no further! The UChicago Jonas Center Symposium is for you! Please get in touch if you're interested or, better yet, register and join us! cme.uchicago.edu/JCCTS2024

NEW - Regulatory Considerations for Genome-Edited T-cell Therapies, on navigating complexities in bringing new technologies to regulatory submissions, clinical trials. From @NathanSinghLab & colleagues @PennMedicine @CIR_AACR #geneediting #CRISPR aacrjournals.org/cancerimmunolr…

Taken the day @JoeBiden announced his candidacy in 2019. A patriot that history will remember for doing the right, hard thing, over and over. We are lucky to have had him as President. Now, let's kick it into gear for @VP @KamalaHQ and finish this!

Now online in @CD_AACR: Rational Protein Engineering to Enhance MHC-independent T Cell Receptors - by Ju-Fang Chang, @NathanSinghLab, and colleagues doi.org/10.1158/2159-8… @WUSTLmed

Huge shout out to Twitter-less Ju-fang Chang, our structural biologist extraordinaire who drove this work from start to finish, and the amazing editorial team @CancerDiscovery. (4/4)

Using advanced modeling tools, we alleviated these conflicts to enhance receptor function across a variety of tumor models. A clear demonstration that design of synthetic immunotherapies requires consideration of de novo protein structures. (3/4)

Are all hybrid antigen receptors as easy to design as CARs? Definitely not! doi.org/10.1158/2159-8… (1/4)

@EvanWeberPhD Wish Twitter had an "unlike" button.

I mean...